Latest Articles
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? - ESMO Daily Reporter
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? ESMO Daily Reporter
Published: June 18, 2026, 2:24 p.m.
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer - Medscape Reference
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer Medscape Reference
Published: June 17, 2026, 2:51 p.m.
Hospital charity launches £1.5m MRI appeal to support 1,300 women and babies every year - Greater Birmingham Chambers of Commerce
Hospital charity launches £1.5m MRI appeal to support 1,300 women and babies every year Greater Birmingham Chambers of Commerce
Published: June 12, 2026, 5:07 a.m.
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies - The Malaysian Reserve
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies The Malaysian Reserve
Published: June 11, 2026, 6:33 a.m.
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies - StreetInsider
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies StreetInsider
Published: June 11, 2026, 5:42 a.m.
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer - The ASCO Post
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer The ASCO Post
Published: June 10, 2026, 4:41 p.m.
Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease - The ASCO Post
Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease The ASCO Post
Published: June 8, 2026, 4:29 p.m.
Mali Barbi: ASCO 2026 Endometrial Cancer Recap Highlights Potential Curative Signal in dMMR Subtype - Oncodaily
Mali Barbi: ASCO 2026 Endometrial Cancer Recap Highlights Potential Curative Signal in dMMR Subtype Oncodaily
Published: June 7, 2026, 6:12 a.m.
Puxitatug Samrotecan Elicits High Response Rate in Select Endometrial Cancers - OncLive
Puxitatug Samrotecan Elicits High Response Rate in Select Endometrial Cancers OncLive
Published: May 30, 2026, 9:59 p.m.
Long-Term RUBY Data Show Potential for Curative Intent With Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer - OncLive
Long-Term RUBY Data Show Potential for Curative Intent With Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer OncLive
Published: May 30, 2026, 12:24 a.m.
Link copied to clipboard!